Dr. Matulonis Discusses Rationale of QUADRA Trial
In Partnership With:
Ursula A. Matulonis, MD, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer.
Ursula A. Matulonis, MD, professor of medicine, Harvard Medical School, chief, Division of Gynecological Oncology, Dana-Farber Cancer Institute, discusses the rationale behind the QUADRA trial for patients with relapsed ovarian cancer. Data from the study were presented at the 2018 ASCO Annual Meeting.
QUADRA was a phase II, single-arm study that evaluated niraparib (Zejula), an oral PARP inhibitor, in patients with relapsed disease who had received >3 prior chemotherapy regimens. Investigators of the study were looking to expand the use of niraparib into patient populations beyond the FDA-approved indication. In patients with homologous recombination deficiency positivity, niraparib led to an objective response rate (ORR) of 29%; the ORR in patients with BRCA mutations was 31%.
In March 2017, the FDA approved niraparib for maintenance therapy of adult patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
